BioCentury | Nov 21, 2020
Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety...
BioCentury | Nov 13, 2020

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

A Cherry in MorphoSys’ hunt for new techMorphoSys AG (Xetra:MOR; NASDAQ:MOR) entered an exclusive licensing agreement with University Hospital Würzburg spinout Cherry Biolabs GmbH for access to its Hemibody platform to discover and develop T...
BioCentury | Nov 7, 2020

Galapagos gains new antifibrotic mechanism through OncoArendi deal

Galapagos’ latest move to expand its early fibrosis pipeline, via a deal with Polish biotech OncoArendi, gives the company access to a new fibrosis-blocking immune mechanism.  Through the exclusive collaboration and licensing agreement, Galapagos N.V....
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

Isolating tumor antigen-specific T cellsScripps Research Institute scientists have described in Cell a method, coined FucoID, to detect and separate T cells that react to tumor-specific antigens from bystander T cells. In FucoID, which is based on...
BioCentury | Oct 30, 2020
Distillery Therapeutics

KSP as a neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Inhibiting the mitotic kinesin KSP could treat neuroblastoma, a pediatric sympathetic nervous system malignancy. In neuroblastoma patients, high KSP expression in tumors was associated with high-risk neuroblastoma, advanced tumor...
BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which met its primary endpoint in the Phase IIa NOVESA trial in patients with cutaneous systemic sclerosis.  The company gained €7.55 (7%) to €115.50 on Euronext and $11.05...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer Interrupting the interaction between PP2A catalytic subunit PPP2CA and STRN3, a regulatory subunit, could treat gastric cancer. In patients, STRN3 expression...
BioCentury | Aug 19, 2020
Product Development

Filgotinib setback a blow to building franchise around Gilead-Galapagos therapy

After a surprise setback at FDA for filgotinib in rheumatoid arthritis caused Galapagos to lose more than $3 billion in market cap, two investors who spoke with BioCentury questioned whether the JAK inhibitor still had a chance to...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

Horizon raising cash after Tepezza beats sales estimate Shares of Horizon Therapeutics plc (NASDAQ:HZNP) rose 24% Wednesday, adding nearly $2.9 billion to the company’s market cap after a 2Q20 earnings report that showed that sales...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
Items per page:
1 - 10 of 959